Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drug candidates for treating severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug candidates in clinical trials for treating multiple types of cancer and various drug candidates in the preclinical stage of development. Its oncology product portfolio includes Ganetespib, an Hsp90 inhibitor in various phase 1, 2, and 3 clinical trail programs for various types of cancers, including non-small cell lung cancer, gastrointestinal stromal tumors, hematologic cancers, colorectal cancer, gastric cancer, small cell lung cancer, ocular melanoma, pancreatic cancer, prostate cancer, breast cancer, hepatocellular cancer, and solid tumors; Elesclomol, a mitochondria-targeting agent in phase 2 clinical trails for non-small cell lung cancer and ovarian cancer, as well as in phase 1 clinical trail for acute myeloid leukemia; STA-9584, a vascular disrupting agent in preclinical development stage for prostate cancer; and various Hsp90 inhibitors in preclinical development stage for cancers. The company